GILENYA® has a pregnancy registry—click here to learn more.
*From January - May 2013, most eligible patients paid a $0 co-pay. Call 1-800-GILENYA for details. People for whom GILENYA has been prescribed are required to report any benefits they receive through the GILENYA Prescription Co-Pay Support Program to their commercial insurance company. This offer is not valid for prescriptions for which payment may be made in whole or in part under federal or state health programs, including but not limited to Medicare or Medicaid. This program is subject to termination or modification at any time.
†GILENYA can result in a slow heart rate when first taken. Your first dose will be given in a medical facility where you will be watched for at least 6 hours. If you stop taking GILENYA for more than 14 days after your first month of treatment, you will need to repeat this observation.
Studies showed that GILENYA reduced the frequency of relapses by 52% in a 1-year study vs Avonex®, and by 54% in a 2-year study vs placebo. At the 1-year mark in a clinical trial, 83% of people on GILENYA were relapse-free. Of those people taking Avonex instead, 70% were relapse-free at year's end. In a separate study, 70% of the people on GILENYA were relapse-free for the entire 2 years. For the people taking placebo during that time, 46% of them stayed relapse-free.
Every GILENYA Guide on our site is a GILENYA patient who has said, "HEY MS, Take This!" They have been compensated by Novartis for their involvement. Individual results may vary.
Speak up and share your message. Tell MS how you really feel by posting your message on the GILENYA® map.
Please know we may not be able to post part or all of your message — but we're still listening! To help ensure your message gets posted, please read our Community Guidelines before proceeding:
Do not include medical advice or any non-approved use of GILENYA
No profane, indecent, or inappropriate language in your message or image, please (a no-no)
Avoid using your full name and/or e-mail address in your message, so this personal information remains private and protected
Do not include spam, such as links to, or URLs for, other Web sites or social networks in your message
Avoid mention of side effects from GILENYA. We take drug product safety seriously. If you are experiencing a side effect, we encourage you to report it to the FDA directly at www.fda.gov/medwatch or
Please note that in order to comply with our Community Guidelines as well as the FDA's Prescription Drug Advertising Guidelines, your statement may be subject to modification, while maintaining the spirit of your message. Your photo and statement may be used in other GILENYA marketing materials.
You are now leaving the GILENYA® (fingolimod) site and moving to an external Web site independently operated and not managed by Novartis Pharmaceuticals Corporation.
Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel or click OK to continue.